secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0001157523-22-000945
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q2 product revenue $214M (+33%); AMVUTTRA FDA approved; guidance reiterated
--------------------------------------------------------------------------------

- Q2 net product revenues $214M: ONPATTRO $153M, GIVLAARI $45M, OXLUMO $15M, up 33% YoY.
- FDA approved AMVUTTRA (vutrisiran) for hATTR polyneuropathy; 133 start forms in first weeks.
- GAAP net loss $277M ($2.29/share) vs $190M loss year ago; non-GAAP loss $246M ($2.03).
- Reiterated FY2022 guidance: combined product revenue $870-$930M, R&D+SG&A $1.62-$1.70B.
- Expects APOLLO-B topline results within 3 weeks; cash $2.11B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000115752322000945/0001157523-22-000945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000115752322000945/a52793912.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer